SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%
Wed, 14 Aug

SUN PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:

SUN PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-18*
3
Mar-19*
3
Jun-19*
QoQ ChangeYoY Change
Net SalesRs m72,24271,63983,74416.9%15.9%
Other incomeRs m1,9982,8152,130-24.3%6.6%
TurnoverRs m74,23974,45585,87415.3%15.7%
ExpensesRs m56,17561,47163,7883.8%13.6%
Gross profitRs m16,06710,16819,95696.3%24.2%
DepreciationRs m4,0164,5414,5710.7%13.8%
InterestRs m1,3091,5001,041-30.6%-20.5%
Profit before taxRs m12,7396,94216,474137.3%29.3%
TaxRs m1,639-2881,461-10.9%
Profit after taxRs m11,1017,23115,014107.6%35.3%
Gross profit margin%22.214.223.8
Effective tax rate%12.9-4.18.9
Net profit margin%15.09.717.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 15.9% on a year-on-year (YoY) basis. The expenses were up by 13.6% YoY during the same period.
  • The company's operating profit increased by 24.2% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 23.8% in 1QFY20 as against 22.2% in 1QFY19.
  • Depreciation charges increased by 13.8% and finance costs declined by 20.5% YoY, respectively.
  • Other income increased by 6.6% YoY during the quarter.
  • Net profit for the quarter increased by 35.3% YoY. Net profit margins during the quarter increased from 15.0% in 1QFY19 to 17.5% in 1QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 16.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.8% QoQ during the same period.
  • The company's operating profit increased by 96.3% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 23.8% in 1QFY20 as against 14.2% in 4QFY19.
  • Net profit for the quarter increased by 107.6% QoQ, while net profit margins increased from 9.7% in 4QFY19 to 17.5% in 1QFY20.

To see how SUN PHARMA has performed over the last eight quarters,please visit here.

SUN PHARMA Share Price Performance

Over the last one year,SUN PHARMA share price has moved down from Rs 601.7 to Rs 416.7, registering a Loss of Rs 185.0 or around 30.7%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,484.3 (down 0.7%). Over the last one year it has moved down from 14,687.0 to 12,484.3, a gain of 2,203 points (down 15.0%).

Overall, the S&P BSE SENSEX is down 0.6% over the year.

Current Valuations

At the current price of Rs 416.7, the price to earnings (P/E) ratio of SUN PHARMA stands at 28.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.4 times.

Equitymaster requests your view! Post a comment on "SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%". Click here!

  

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 8, 2020 02:05 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS